Our methodology for labelling and analysing whole CAR T cells is widely used for cross-reactivity screening of the finalised engineered CAR T cells. The Retrogenix technology is a standard IND-enabling safety assessment tool for developers of novel CAR T cell therapies.
Screen scFvs or whole CAR T cells
Retrogenix has two approaches for CAR T cell cross-reactivity screening:
- Screen the antigen recognition element – the scFv / antibody
- Screen whole engineered CAR T cells
Early specificity screening helps to de-risk programs and enable selection of the right scFv candidates in order to maximise the chances of producing the most promising CAR T therapy. This can be followed later by more thorough screening of the whole engineered T cell (or the final scFv) to provide a more in-depth assessment of off-target liability. As there may be a discordance between the off-target profile of the original antibody / scFv and the final engineered T cell it is possible to screen both to ensure that the binding profile has not been altered during development.
Find out more: